Kwality Pharmaceuticals Ltd (KPL) — concall transcript | 30 June 2026

30 June 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Kwality Pharmaceuticals reported Q1 FY27 results with oncology revenue at 20% of total, down from 26%, and reaffirmed FY27 revenue guidance of INR700+ crores with 26-27% EBITDA margins.

🔄 What Changed

Oncology revenue share decreased from 26% to 20% of total revenue.

🔮 What's Next

FY27 revenue guidance of INR700+ crores with 26-27% EBITDA margins; long-term target of INR1,500 crores revenue by FY30 with 30%+ EBITDA margins.

💡 Investor Takeaway

The company is shifting focus to oncology growth and global expansion while targeting higher margins and revenue by FY30.

Kwality Pharmaceuticals reported Q1 FY27 results with oncology revenue at 20% of total, down from 26%, and reaffirmed FY27 revenue guidance of INR700+ crores with 26-27% EBITDA margins. Management highlighted upcoming Erythropoietin trials starting November-December 2026, new product registrations across 70-80 countries, and a planned new global auditor appointment in Q3/Q4 FY27. They outlined long-term targets of INR1,500 crores revenue by FY30 with 30%+ EBITDA margins, while addressing margin pressures and working capital improvements.

📄 View Original Announcement (PDF)

📊 Stock Analysis — KPL ✨ Ask AI About This

About Kwality Pharmaceuticals Ltd (KPL)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹3,763.5 CrP/E: 46.4ROE: 24.4%ROCE: 25.4%

View full KPL stock details →

📡 Get AI alerts when KPL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track KPL — Free

💡 Ask AI about this filing

"When will Erythropoietin trials begin and what is the expected market entry timeline?""What is the projected revenue contribution from hormone and biosimilar products by FY30?""How will the new global auditor appointment impact regulatory compliance and investor confidence?"

Ask AI Free →

📊 More KPL filings

Announcement — 28 September 2026Kwality Pharmaceuticals Ltd announced that its trading window will close on October 1, 2026, remaini...
🟡 Voting Results — 2 September 2026Kwality Pharmaceuticals Limited held its 43rd Annual General Meeting on August 31, 2026, where share...
🟡 Board Meeting — 2 September 2026Kwality Pharmaceuticals announced at its August 31, 2026 AGM the regularization of Mr. Swanith Kapoo...
🟡 Board Meeting — 31 August 2026Kwality Pharmaceuticals held its 43rd AGM on August 31, 2026 via video conference, with all director...
🟡 concall transcript — 31 March 2026Kwality Pharmaceuticals reported FY26 revenue of INR503 crores (up 36% YoY) and PAT of INR67 crores ...

See all KPL filings →

🔥 Also filed on 30 June 2026

AMBERAmber Enterprises India LimitedAnnouncement CGPOWERCG Power and Industrial Solutions LimitedAnnual Report ZEEMEDIAZee Media Corporation LimitedCorporate Action ZENSARTECHZensar Technologies LimitedCorporate Action ANTHEMAnthem Biosciences LimitedAnnual Report CHENNPETROChennai Petroleum Corporation LimitedAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when KPL files new disclosures

Track KPL filings, board meetings, and corporate actions. Free email alerts at 5 PM.